Literature DB >> 11013289

Problematic WHO reclassification of myelodysplastic syndromes. Members of the International MDS Study Group.

P Greenberg, J Anderson, T de Witte, E Estey, P Fenaux, P Gupta, T Hamblin, E Hellstrom-Lindberg, A List, G Mufti, R Neuwirtova, K Ohyashiki, D Oscier, G Sanz, M Sanz, C Willman.   

Abstract

Entities:  

Mesh：

Year:  2000        PMID： 11013289     DOI： 10.1200/JCO.2000.18.19.3447

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  10 in total

1.  The National MDS Natural History Study: design of an integrated data and sample biorepository to promote research studies in myelodysplastic syndromes.

Authors:  Mikkael A Sekeres; Steven D Gore; Donald M Stablein; Nancy DiFronzo; Gregory A Abel; Amy E DeZern; Jesse D Troy; Dana E Rollison; John W Thomas; Myron A Waclawiw; Jane Jijun Liu; Tareq Al Baghdadi; Matthew J Walter; Rafael Bejar; Edward J Gorak; Daniel T Starczynowski; James M Foran; James R Cerhan; Lynn C Moscinski; Rami S Komrokji; H Joachim Deeg; Pearlie K Epling-Burnette
Journal:  Leuk Lymphoma       Date:  2019-05-21

Review 2.  Impact of growth factors in the regulation of apoptosis in low-risk myelodysplastic syndromes.

Authors:  R Tehranchi
Journal:  Med Oncol       Date:  2006       Impact factor: 3.064

3.  NCCN Clinical Practice Guidelines in Oncology: myelodysplastic syndromes.

Authors:  Peter L Greenberg; Eyal Attar; John M Bennett; Clara D Bloomfield; Carlos M De Castro; H Joachim Deeg; James M Foran; Karin Gaensler; Guillermo Garcia-Manero; Steven D Gore; David Head; Rami Komrokji; Lori J Maness; Michael Millenson; Stephen D Nimer; Margaret R O'Donnell; Mark A Schroeder; Paul J Shami; Richard M Stone; James E Thompson; Peter Westervelt
Journal:  J Natl Compr Canc Netw       Date:  2011-01       Impact factor: 11.908

4.  Reproducibility of the World Health Organization 2008 criteria for myelodysplastic syndromes.

Authors:  Leonor Senent; Leonor Arenillas; Elisa Luño; Juan C Ruiz; Guillermo Sanz; Lourdes Florensa
Journal:  Haematologica       Date:  2012-10-12       Impact factor: 9.941

5.  Myelodysplastic syndromes: clinical practice guidelines in oncology.

Authors:  Peter L Greenberg; Eyal Attar; John M Bennett; Clara D Bloomfield; Uma Borate; Carlos M De Castro; H Joachim Deeg; Olga Frankfurt; Karin Gaensler; Guillermo Garcia-Manero; Steven D Gore; David Head; Rami Komrokji; Lori J Maness; Michael Millenson; Margaret R O'Donnell; Paul J Shami; Brady L Stein; Richard M Stone; James E Thompson; Peter Westervelt; Benton Wheeler; Dorothy A Shead; Maoko Naganuma
Journal:  J Natl Compr Canc Netw       Date:  2013-07       Impact factor: 11.908

Review 6.  Radionuclide imaging of bone marrow disorders.

Authors:  Ali Agool; Andor W J M Glaudemans; Hendrikus H Boersma; Rudi A J O Dierckx; Edo Vellenga; Riemer H J A Slart
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-07-13       Impact factor: 9.236

7.  Azacitidine front-line in 339 patients with myelodysplastic syndromes and acute myeloid leukaemia: comparison of French-American-British and World Health Organization classifications.

Authors:  Lisa Pleyer; Sonja Burgstaller; Reinhard Stauder; Michael Girschikofsky; Heinz Sill; Konstantin Schlick; Josef Thaler; Britta Halter; Sigrid Machherndl-Spandl; Armin Zebisch; Angelika Pichler; Michael Pfeilstöcker; Eva-Maria Autzinger; Alois Lang; Klaus Geissler; Daniela Voskova; Dietmar Geissler; Wolfgang R Sperr; Sabine Hojas; Inga M Rogulj; Johannes Andel; Richard Greil
Journal:  J Hematol Oncol       Date:  2016-04-16       Impact factor: 17.388

Review 8.  Acute myeloid leukemia - strategies and challenges for targeting oncogenic Hedgehog/GLI signaling.

Authors:  Fritz Aberger; Evelyn Hutterer; Christina Sternberg; Pedro J Del Burgo; Tanja N Hartmann
Journal:  Cell Commun Signal       Date:  2017-01-25       Impact factor: 5.712

Review 9.  Myelodysplastic syndromes: moving towards personalized management.

Authors:  Eva Hellström-Lindberg; Magnus Tobiasson; Peter Greenberg
Journal:  Haematologica       Date:  2020-05-21       Impact factor: 9.941

10.  EZH2 mutations are related to low blast percentage in bone marrow and -7/del(7q) in de novo acute myeloid leukemia.

Authors:  Xiuli Wang; Haiping Dai; Qian Wang; Qinrong Wang; Yang Xu; Ying Wang; Aining Sun; Jia Ruan; Suning Chen; Depei Wu
Journal:  PLoS One       Date:  2013-04-17       Impact factor: 3.240
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.